Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6170430rdf:typepubmed:Citationlld:pubmed
pubmed-article:6170430lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0018557lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0025500lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0004475lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0113600lld:lifeskim
pubmed-article:6170430lifeskim:mentionsumls-concept:C0070165lld:lifeskim
pubmed-article:6170430pubmed:issue11-12lld:pubmed
pubmed-article:6170430pubmed:dateCreated1982-1-28lld:pubmed
pubmed-article:6170430pubmed:abstractTextAsbestos-induced peritoneal mesothelioma 10-24 serially transplanted in Syrian golden hamsters was used to test responses to seven drugs as single agents. Compared to saline-treated controls, the average survival time increased 51%-85% with azactitidine, 42%-60% with aziridinylbenzoquinone, 43% with cisplatin, and 35%-45% with PCNU. No cures were achieved. Therapeutic responses were not observed with dactinomycin, dianhydroxyanthracenedione, or DTIC.lld:pubmed
pubmed-article:6170430pubmed:languageenglld:pubmed
pubmed-article:6170430pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:citationSubsetIMlld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6170430pubmed:statusMEDLINElld:pubmed
pubmed-article:6170430pubmed:issn0361-5960lld:pubmed
pubmed-article:6170430pubmed:authorpubmed-author:DavisSSlld:pubmed
pubmed-article:6170430pubmed:authorpubmed-author:SmithW EWElld:pubmed
pubmed-article:6170430pubmed:authorpubmed-author:HubertD DDDlld:pubmed
pubmed-article:6170430pubmed:authorpubmed-author:HoliatS MSMlld:pubmed
pubmed-article:6170430pubmed:issnTypePrintlld:pubmed
pubmed-article:6170430pubmed:volume65lld:pubmed
pubmed-article:6170430pubmed:ownerNLMlld:pubmed
pubmed-article:6170430pubmed:authorsCompleteYlld:pubmed
pubmed-article:6170430pubmed:pagination1113-5lld:pubmed
pubmed-article:6170430pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:meshHeadingpubmed-meshheading:6170430-...lld:pubmed
pubmed-article:6170430pubmed:articleTitleChemotherapeutic trials with hamster mesothelioma 10-24: responses to azacitidine, aziridinylbenzoquinone, cisplatin, and PCNU.lld:pubmed
pubmed-article:6170430pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6170430pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed